journal
MENU ▼
Read by QxMD icon Read
search

Open Access Rheumatology: Research and Reviews

journal
https://read.qxmd.com/read/30774485/sj%C3%A3-gren-s-syndrome-and-systemic-lupus-erythematosus-links-and-risks
#1
REVIEW
Sandra Gofinet Pasoto, Victor Adriano de Oliveira Martins, Eloisa Bonfa
Systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS) may coexist, and they are chronic complex disorders, with an autoimmune background, multifactorial etiology, multiple circulating autoantibodies, and variable prognosis. The prominent feature of SS is the impairment of the lacrimal and salivary glands leading to sicca symptoms. This disease may be classified as primary Sjögren's syndrome (pSS), or secondary Sjögren's syndrome (sSS) since it is often associated to other autoimmune disorders, principally SLE, rheumatoid arthritis, and systemic sclerosis...
2019: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/30774484/enthesitis-related-arthritis-current-perspectives
#2
REVIEW
Rutviz Rajendra Mistry, Pallavi Patro, Vikas Agarwal, Durga Prasanna Misra
In this narrative review, we overview the recent literature on enthesitis-related arthritis (ERA). For the purpose of our review, we searched Scopus for recent articles on this subject from 2013 onward, including some classic older articles for perspective. ERA is a juvenile idiopathic arthritis (JIA) subtype more common in males, associated in a majority with human leucocyte antigen B27. Such children generally present with asymmetric oligoarthritis or polyarthritis, predominantly of lower limb joints, associated with enthesitis or sacroiliitis...
2019: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/30655709/correlation-between-xerostomia-index-clinical-oral-dryness-scale-and-esspri-with-different-hyposalivation-tests
#3
Ola Hijjaw, Mohammad Alawneh, Khaled Ojjoh, Hazem Abuasbeh, Ahmad Alkilany, Nabeel Qasem, Mohammad Al-Essa, Saif Aldeen AlRyalat
Background and objective: Xerostomia is a subjective measure of dry mouth, while hyposalivation is an objective measure of reduced saliva flow rate. In this study, we aim to assess the association between commonly used xerostomia scoring systems, with different hyposalivation measures among Sjogren Syndrome (SS) patients. Methods: In a cohort of SS patients, we assessed xerostomia using Xerostomia index, clinical oral dryness scale (CODS), and the European League Against Rheumatism SS Patient-Reported Index (ESSPRI), and we assessed hyposalivation using unstimulated whole saliva flow (UWS), stimulated whole saliva flow (SWS), and stimulated parotid flow (SPF)...
2019: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/30613169/review-of-biologics-biosimilars-and-intended-copies-in-rheumatology-and-current-practice-in-iraq
#4
REVIEW
Nizar Abdulateef Al Ani, Faiq I Gorial, Saad Al-Sulaitti, Jasmine Abbas Humadi, Nabaa Ihsan Awadh, Mohamed Mounir, Yasser El Dershaby, Heather Jones, Nancy Sunna
Biologic therapies are an important option in the treatment of patients with rheumatic disease. As the development of potential biosimilars increases, many countries are following the guidelines developed by the WHO, European Medicines Agency, or US Food and Drug Administration to create country-specific regulations for the review and approval of these products. Iraq does not yet have such regulations, and this presents a potential safety concern for patients. The analytical, nonclinical, and clinical data requirements for approval of a potential biosimilar are specific and scientifically rigorous...
2019: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/30584379/clinical-assessment-and-ultrasonography-in-the-follow-up-of-enthesitis-in-patients-with-spondyloarthritis-a-multicenter-ultrasound-study-in-daily-clinical-practice
#5
Wolfgang Hartung, Axel Nigg, Johannes Strunk, Björn Wolff
Objectives: The aim of this study was to compare the clinical Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) and an established ultrasound enthesitis score following treatment change in patients with spondyloarthritis and enthesitis with respect to the sensitivity to change and health-related quality of life. Materials and methods: About 145 patients with active ankylosing spondylitis (n=65), psoriatic arthritis without (n=66) or with (n=14) axial involvement undergoing intensification of their treatment were included in this multicenter study...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/30568519/treatment-persistence-of-subcutaneous-tnf-inhibitors-among-australian-patients-with-immune-mediated-rheumatic-disease-imrd
#6
Mustafa Acar, Prabhjot Juneja, Malcolm Handel
Introduction: To describe the persistence of treatment with subcutaneous tumor necrosis factor inhibitors (TNFi) adalimumab, etanercept, and golimumab in immune-mediated rheumatic disease (rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis) by treatment sequence (first-line treatment, second-line or further lines of treatment). Methods: A retrospective cohort analysis was conducted using the Australian Commonwealth Department of Human Services Pharmaceutical Benefits Scheme 10% sample data from January 1, 2010, to June 30, 2016...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/30425593/impact-of-pegloticase-on-patient-outcomes-in-refractory-gout-current-perspectives
#7
REVIEW
Rita N Cunha, Renata Aguiar, Filipa Farinha
Gout is currently the most frequent cause of inflammatory arthritis worldwide and is responsible for poor health-related quality of life and loss of work productivity. It is caused by high levels of serum urate, leading to the deposition of monosodium urate crystals in joints and soft tissues. This condition is associated with acute flares and, if untreated or refractory, chronic and potentially destructive arthritis and tophi formation. Pegloticase is a recombinant, pegylated uricase used in the treatment of gout patients who fail conventional urate-lowering therapy...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/30323693/novel-treatments-for-osteoarthritis-an-update
#8
REVIEW
Yong Wu, En Lin Goh, Dong Wang, Shaocheng Ma
Osteoarthritis is the most prevalent chronic joint condition worldwide. The principles of osteoarthritis treatment are to alleviate pain and stiffness as well as maintain function, with current consensus guidelines recommending the use of a combination of conservative measures including physical therapy, analgesia, and surgical interventions such as arthroplasty. In recent years, several pharmacological therapies have emerged as potential alternatives. Although a disease-modifying osteoarthritis drug has yet to be identified, promising results have been reported in recent trials especially with serotonin-norepinephrine reuptake inhibitors, IL-1 antagonists, and antibodies to nerve growth factor...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/30233261/low-mortality-rate-in-italian-rheumatoid-arthritis-patients-from-a-tertiary-center-putative-implication-of-a-low-anti-carbamylated-protein-antibodies-prevalence
#9
Daniela Iacono, Elvira Favoino, Alessia Borgia, Serena Fasano, Ilenia Pantano, Virginia D'Abrosca, Giuseppe Picillo, Rosa Daniela Grembiale, Federico Perosa, Gabriele Valentini
Background and objective: Anti-carbamylated protein antibodies (anti-CarP Ab) represent a novel kind of autoantibodies specificity detectable in the sera of patients with rheumatoid arthritis (RA). They have been recently reported to be associated with increased mortality in Spanish patients with RA. The aim of our study was to compare the incidence mortality rates (IMRs) detected in RA patients from a tertiary Italian center with those reported in other European tertiary centers and to evaluate the putative role of anti-CarP Ab in modulating the low IMR detected in our patients...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/30214327/macrophage-activation-syndrome-early-diagnosis-is-key
#10
REVIEW
Butsabong Lerkvaleekul, Soamarat Vilaiyuk
Macrophage activation syndrome (MAS) is a life-threatening condition, and it is a subset of hemophagocytic lymphohistiocytosis (HLH). The clinical features include a persistent high-grade fever, hepatosplenomegaly, lymphadenopathy, hemorrhagic manifestations, and a sepsis-like condition. From the clinical features, it is usually difficult to differentiate between a true sepsis, disease flare-ups, or MAS. Although the laboratory abnormalities are similar to those of a disseminated intravascular coagulation, which shows pancytopenia, coagulopathy, hypofibrinogenemia, and an elevated d-dimer test, it can also be a late stage of MAS...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/30147384/a-rare-case-of-suicidal-ideation-related-to-adalimumab-use
#11
Fatima Jafri, Amanda Sammut
Introduction: Patients undergoing treatment with an anti-tumor necrosis factor-alpha (TNF- α ) agent can, as an adverse event, develop anti-TNF- α -induced lupus (ATIL). Neuropsychiatric symptoms such as depression and suicidal ideations are not commonly seen in patients who develop ATIL. We describe a case of a 56-year-old female who developed ATIL and suicidal ideations while on Adalimumab. Case presentation: A 56-year-old female with rheumatoid arthritis (RA) and no known prior history of systemic lupus erythematosus or depression presented with suicidal ideations, joint pains and a malar rash after a recent change in her Adalimumab dose...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/30127649/treatment-patterns-health-care-resource-utilization-and-costs-of-rheumatoid-arthritis-patients-in-italy-findings-from-a-retrospective-administrative-database-analysis
#12
Walid Fakhouri, Pedro Lopez-Romero, Silvia Antonelli, Serena Losi, Veronica Rogai, Stefano Buda, Diego Sangiorgi, Valentina Perrone, Luca Degli Esposti
Objectives: This study aimed to: 1) describe treatment patterns and drug utilization profile (in terms of therapeutic strategy used, switch, persistence and drug consumption variation) among adult patients affected by rheumatoid arthritis (RA), and 2) estimate the health care resource utilization and its associated direct cost for the management of RA patients. Methods: A retrospective cohort analysis, using administrative databases of six Local Health Units in Italy, was performed...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/30013407/treatment-of-rheumatoid-arthritis-in-the-usa-premature-use-of-tumor-necrosis-factor-inhibition-and-underutilization-of-concomitant-methotrexate
#13
James R O'Dell, Stanley B Cohen, J Carter Thorne, Joel Kremer
Purpose: The objective of this study was to assess the treatment for patients with rheumatoid arthritis (RA) in the USA. Patients and methods: This study entailed analysis of claims data for patients with RA who initiated treatment with oral methotrexate (MTX) or a biologic in 2009 (n=48,910) or 2012 (n=107,636) and had follow-up for 4 years (2009 cohort) or 2 years (2012 cohort). Results: A biologic was initiated before MTX for 27% of the 2009 cohort and 36% of the 2012 cohort...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/30013406/pediatric-rheumatology-addressing-the-transition-to-adult-orientated-health-care
#14
REVIEW
Sara Sabbagh, Tova Ronis, Patience H White
The transition from pediatric to adult health care is often a challenging process due to multiple interwoven complexities, especially for children with chronic medical conditions. Health care transition (HCT) is a process of moving from a pediatric to an adult model of health care with or without a transfer to a new clinician. This paper focuses on what is known about HCT for youth and young adults (Y/YA) with rheumatic diseases within a larger context of HCT recommendations. HCT barriers for youth, families, and providers and current evidence for a structured HCT processes are reviewed...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/29942167/impact-of-systemic-juvenile-idiopathic-arthritis-still-s-disease-on-adolescents-as-evidenced-through-social-media-posts
#15
Renee F Modica, Kathleen G Lomax, Pamela Batzel, Armelle Cassanas
Purpose: To understand the experience of adolescent systemic juvenile idiopathic arthritis (SJIA) patients and those of their parents based on their social media posts. Methods: English language posts related to SJIA, Still's disease, or juvenile arthritis were collected and analyzed. Results: In total, 71 posts created between 2009 and 2015 on 15 websites were identified in November 2015. Of the 32 unique authors, 17 were SJIA patients aged 13-20 years (40 posts), 7 were mothers of SJIA patients (12 posts), and 8 patients had unspecified forms of juvenile arthritis (19 posts)...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/29922101/metabolic-syndrome-in-adults-with-a-history-of-juvenile-arthritis
#16
Sangeeta Sule, Kevin Fontaine
Objective: The objective of this study was to determine the risk of obesity and metabolic syndrome in adults with a history of juvenile arthritis (JA). Methods: Using the National Health and Nutrition Examination Survey (NHANES), we compared the characteristics of respondents with arthritis (JA vs rheumatoid arthritis [RA]) to those of the control group without arthritis. We used logistic regression analyses, controlling for age, race, and gender, to determine the ORs for metabolic syndrome...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/29881314/comparative-assessment-of-fracture-risk-among-osteoporosis-and-osteopenia-patients-a-cross-sectional-study
#17
Snezana Tomasevic-Todorovic, Atina Vazic, Abukari Issaka, Fahad Hanna
Background: Both osteoporosis and osteopenia remain worldwide public health concerns. They both lead to bone fractures, which can lead to disability and burden on those who are afflicted. Objectives: To assess and compare fracture risk between these two groups of patients. Patients and methods: Our cross-sectional study included 82 patients (46 with osteoporosis and 36 with osteopenia) with an average age of 63±9.33 years, who received treatment at the Clinic for Medical Rehabilitation, Clinical Center of Vojvodina in Novi Sad, Serbia...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/29872356/serum-heat-shock-protein-65-antibody-levels-are-elevated-but-not-associated-with-disease-activity-in-patients-with-rheumatoid-arthritis-and-ankylosing-spondylitis
#18
Hasan Ulusoy, Gurkan Akgol, Arif Gulkesen, Arzu Kaya, Gul Ayden Kal, Dilara Kaman, Turkan Tuncer
Objectives: Heat-shock proteins (HSPs) have gained increased interest for their role in autoimmune disorders. These proteins are targeted by the immune system in various autoimmune diseases. The aim of this study was to assess the serum heat-shock protein-65 antibody (anti-HSP65) levels and their clinical significance in patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Patients and methods: A total of 30 patients with RA, 30 patients with AS, and 30 healthy controls were enrolled in this study...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/29849470/systematic-clinical-evidence-review-of-nasha-durolane-hyaluronic-acid-for-the-treatment-of-knee-osteoarthritis
#19
REVIEW
Ross Leighton, Jane Fitzpatrick, Helen Smith, Daniela Crandall, Carl R Flannery, Thierry Conrozier
Background: Pain and limitations in joint mobility associated with knee osteoarthritis (OA) are clinically challenging to manage, and advanced progression of disease can often lead to total knee arthroplasty. Intra-articular injection of hyaluronic acid (HA), also referred to as viscosupplementation, is a non-surgical treatment approach for OA, the effectiveness of which may depend on the HA composition, and the length of time over which it resides in the joint. One of the available options for such therapies includes NASHA (Durolane HA), a non-animal, biofermentation-derived product, which is manufactured using a process that stabilizes the HA molecules to slow down their rate of degradation and produce a unique formulation with a terminal half-life of ~1 month...
2018: Open Access Rheumatology: Research and Reviews
https://read.qxmd.com/read/29765257/spotlight-on-certolizumab-pegol-in-the-treatment-of-axial-spondyloarthritis-efficacy-safety-and-place-in-therapy
#20
REVIEW
Josefina Marin, María Laura Acosta Felquer, Enrique R Soriano
Certolizumab pegol (CZP) is a pegylated humanized tumor necrosis factor-α inhibitor (TNFi) approved for the treatment of ankylosing spondylitis (AS) in the USA and for AS and non-radiographic axial spondyloarthritis (nr-axSpA) in Europe and in some Latin American countries. CZP lacks Fc region, preventing complement fixation and cytotoxicity mediated by antibody; CZP does not actively cross the placenta, unlike other TNFi. RAPID-axSpA study is a Phase III trial conducted in patients with AS and nr-axSpA as double blind and placebo controlled to week 24, dose blind to week 48 and open label to week 204...
2018: Open Access Rheumatology: Research and Reviews
journal
journal
53801
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"